Alternatives to France – Laboratory reagents – FOURNITURE DE CONSOMMABLES ET REACTIFS DE BIOLOGIE POUR LABORATOIRE DE PHARMACO-TOXICOLOGIE DU CHU DE NIMES

France – Radiotherapy devices and supplies – FOURNITURE D’EQUIPEMENTS ET LOGICIELS DE RADIOTHERAPIE ET PRESTATIONS ASSOCIEES

France – Orthopaedic supplies – Fourniture de dispositifs médicaux de type orthèses et prothèses pour le Centre Hospitalier de CALAIS (CHC)

France – Medical equipments, pharmaceuticals and personal care products – Fournitures de dispositifs médicaux stériles : trousses et packs à façon

Expected Outcome: This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: Fully programmable industry-ready quantum simulators based on 10.000 neutral atoms in a scalable architecture, accessible via cloud platforms, and with the possibility of integrating them into high-performance computing environments. Fully programmable platform for neutral-atom quantum computing capable of both analogue quantum operations and gate-based computing with 1.000 physical qubits and a clear path to further scalability to 10.000 physical qubits. Coherence time of the order of hundreds of interaction times and infidelity of operations below 1%. Demonstration of quantum simulation and/or computing operating beyond classical computability, validated through benchmarking with classical methods. New real-world applications across science and industry (at least two) (e.g: in the energy and health sectors) The software stack for these applications, including enhanced software for verification, algorithm implementation, and user programming interfaces. Demonstration of the full quantum stack – including quantum control, electronic…

NIOSH is encouraging the submission of an application from qualified organizations for a National Center for Construction Safety and Health Research and Translation. Applicants are encouraged to propose multidisciplinary approaches and coordination for impactful applied and intervention research, hazard identification, and controls; develop partnerships for implementing prevention and intervention activities; and serve as a leader in research translation and research-to-practice for the protection of construction workers in the U.S. The Center will accomplish these goals by integrating and advancing research, research translation, best practices, policy and guidance, and capacity building. Center work should consider the NIOSH strategic plan and NORA construction research objectives. Center structure should take advantage of diverse scientific resources and focus on national worker safety and health issues. Centers should emphasize the creation and implementation of evidence-based solutions that address important construction industry safety and health problems. Collaborations with other academic institutions, nonprofit organizations, and other occupational safety and health-focused groups are expected. Applicants must concisely describe the occupational health burden of important safety and health issues in the construction industry and discuss how focused research and outreach activities will help alleviate the burden and reduce numbers. Applicants should also clearly articulate the anticipated impacts of the Center’s proposed work, both during the project period and beyond.

Denmark – Pharmaceutical products – Amgros 2027 1.487.a

Sweden – CT scanners – Datortomografer

France – Household-refuse collection services – Collecte des ordures ménagères résiduelles et collectes sélectives

Spain – Medical consumables – Suministro de equipos de cobertura quirúrgica desechable, material auxiliar y elementos fungibles asociados para la Osi Bilbao Basurto, y puesta a disposición de un modelo de gestión logística automat

France – Building-cleaning services – Nettoyage des biens immobiliers de la Métropole de Lyon

Romania – Various medicinal products – Furnizare medicamente diverse si medicamente specifice sectiei oncologie

Czechia – Pharmaceutical products – Léčivé přípravky s účinnou látkou RAVULIZUMAB